“Background: Several cases of unusual thrombotic events and thrombocytopenia have developed after vaccination with the recombinant adenoviral vector encoding the spike protein antigen of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (ChAdOx1 nCov-19, AstraZeneca). More data were needed on the pathogenesis of this unusual clotting disorder.
Methods: We assessed the clinical and laboratory features of 11 patients in Germany and Austria in whom thrombosis or thrombocytopenia had developed after vaccination with ChAdOx1 nCov-19…
Results: Of the 11 original patients, 9 were women, with a median age of 36 years (range, 22 to 49). Beginning 5 to 16 days after vaccination, the patients presented with one or more thrombotic events, with the exception of 1 patient, who presented with fatal intracranial hemorrhage. Of the patients with one or more thrombotic events, 9 had cerebral venous thrombosis, 3 had splanchnic-vein thrombosis, 3 had pulmonary embolism, and 4 had other thromboses; of these patients, 6 died. Five patients had disseminated intravascular coagulation.”
© 2023 Massachusetts Medical Society. All rights reserved. Reuse of Content Within a Thesis or Dissertation Content (full-text or portions thereof) may be used in print and electronic versions of a dissertation or thesis without formal permission from the Massachusetts Medical Society (MMS), Publisher of the New England Journal of Medicine. The following credit line must be printed along with the copyrighted material: Reproduced with permission from (scientific reference citation), Copyright Massachusetts Medical Society. Source: https://www.nejm.org/about-nejm/permissions